Thomas Seck, MD, on Expanding Empagliflozin Use for Heart Failure

Dr Thomas Seck, who is the vice president of Clinical Development and Medical Affairs at Boehringer Ingelheim Pharmaceuticals, discusses the EMPERIAL trials, which aim to expand the use of empagliflozin for heart failure.

For more information about the EMPERIAL trials, read the press release here.

For more content related to heart failure, visit HeartFailure360.

Submit Feedback

Name